ArticleExperimental and therapeutic medicine2020
EGCG induces β-defensin 3 against influenza A virus H1N1 by the MAPK signaling pathway.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Dual Antiviral and Immunomodulatory Effects of Phytochemicals in Influenza A Virus Infection: Targeting Key Host Signaling Pathways.MicrobiologyOpen · 2026Review
- Epigallocatechin-3-gallate inhibits replication of influenza A virus via restoring the host methylated genes following infection.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Antiviral Effects and Mechanisms of Active Ingredients in Tea.Molecules (Basel, Switzerland) · 2024Review
- Epigallocatechin gallate attenuated high glucose-induced pancreatic beta cell dysfunction by modulating DRP1-mediated mitochondrial apoptosis pathways.Scientific reports · 2024Article
- Piceatannol as an Antiviral Inhibitor of PRV Infection In Vitro and In Vivo.Animals : an open access journal from MDPI · 2023Article
- Regulation of Host Defense Peptide Synthesis by Polyphenols.Antibiotics (Basel, Switzerland) · 2023Review
- Inhibition of H1N1 byFood science & nutrition · 2023Article
- Therapeutic Effects of Green Tea Polyphenol (‒)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis.International journal of molecular sciences · 2022Review
- Influenza Virus Entry inhibitors.Advances in experimental medicine and biology · 2022Review
- Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity.Frontiers in chemistry · 2022Article
- EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.Molecules (Basel, Switzerland) · 2021Review
- Bioinformatics Analysis and Experimental Validation of Epigallocatechin-3-gallate Against Iopromide-induced Injury in HEK-293 CellsIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin gallate (EGCG) is the main component of green tea, which has been proven to inhibit a variety of viruses, including influenza A virus. However, the mechanism of EGCG against influenza virus remains to be further explored. The mechanism of EGCG against influenza virus was studied. The results showed that EGCG significantly increased the levels of HBD3 mRNA and protein, while the levels of phosphorylation of (p)-p38 MAPK, ERK and JNK after EGCG treatment were significantly up-regulated. p38 MAPK, ERK and JNK inhibitors significantly inhibited the expression of HBD3 induced by EGCG. On the other hand, EGCG significantly inhibited the expression of HA and NP proteins in influenza A virus H1N1, but attenuated the anti-influenza A virus effect of EGCG after silencing HBD3. Thus, the anti-influenza virus effect of EGCG is related to the induction of HBD3 expression. In addition, the expression of EGCG-induced HBD3 is related to the p38 MAPK, ERK and JNK signaling pathways. The research data show that EGCG can induce HBD3 expression through p38 MAPK, ERK and JNK signaling pathway to inhibit the replication of influenza A virus H1N1, providing a new and effective candidate drug for influenza virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.